BME100 f2015:Group11 8amL2

From OpenWetWare
Jump to navigationJump to search
Owwnotebook icon.png BME 100 Fall 2015 Home
Lab Write-Up 1 | Lab Write-Up 2 | Lab Write-Up 3
Lab Write-Up 4 | Lab Write-Up 5 | Lab Write-Up 6
Course Logistics For Instructors
Wiki Editing Help
BME494 Asu logo.png


Name: Kyle Greenzweig
Name: Ryan Tenorio
Name: Your name
Name: Your name
Name: Your name
Name: Your name


Descriptive Statistics

Human Study

human study table

Rat Study

rat study table


Experiment 1

Description of image

Experiment 2

Description of image


Human Study

For the human study, there were more than two groups, so a one-way ANOVA was used for comparison.

Lab 2 Human Study Part 1.png

Lab 2 Human Study Part 2.png

The p-value is less than 0.05, so there was a statistically significant difference.

When completing an ANOVA test, a post-hoc test is useful to compare each of the groups to one another. Lab 2 Human Study Part 3.png

The p-value used for these t-tests was 0.008333. The regular p-value, 0.05, was divided by 6 (the number of comparisons) to get this p-value. All of the values were less than this p-value, so there is a statistically significant difference when comparing every group to each other.

Rat Study

The rat study only consisted of two groups, meaning that a T-test can be used to make the comparison.

Lab 2 Rat Study T-Test.png

The p-value from this T-test is greater than 0.05, meaning there is no statistical difference between groups.


The data from the rat study was inconclusive. Although the averages inferred that there was a linkage between LPS dosage and the amount of Inflammotin, there was a lot of deviation in the data set. There was not a significant enough difference in the data set to conclude that the LPS dosage affected the production of Inflammotin (only a 13% confidence that there was a linkage between 0mg and 10mg). The data from the human study of Inflammotin concluded that there was in fact a relationship between the dosage and the amount of Inflammotin produced. The ANOVA and t-tests determined there was almost 100% confidence that there was a linkage between each LPS dosage (0mg-15mg) and the amount of Inflammotin protein produced in the elderly. Although the rat study was not able to link the LPS dosage with the amount of Inflammotin, the LPS treatment can be concluded to increase the Inflammotin protein levels in the elderly.